Table 3 Clinical response

First line chemotherapy (n = 303)

 Complete response

9 (3.0 %)

 Partial response

43 (14.2 %)

 Stable disease

126 (41.6 %)

Disease control (CR + PR + SD)

178 (58.8 %)

 Progression

99 (32.7 %)

 Non evaluable

26 (8.5 %)

Second line chemotherapy (n = 162)

 Complete response

1 (0.6 %)

 Partial response

9 (5.4 %)

 Stable disease

31 (18.6 %)

Disease control (CR + PR + SD)

41 (24.6 %)

 Progression

78 (46.7 %)

 Non evaluable

48 (28.7 %)

Third line chemotherapy (n = 56)

 Complete response

0

 Partial response

1 (1.8 %)

 Stable disease

2 (3.6 %)

Disease control (CR + PR + SD)

3 (5.4 %)

 Progression

27 (48.2 %)

 Non evaluable

26 (46.4 %)